Evangelos Giamarellos-Bourboulis

Evangelos is a Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens since 2018. He was trained in the Immunology of Infections at the Department of Internal Medicine and Infectious Disease of Radboud University in the Netherlands. In 2012 and 2013 he served as guest Professor of the Department of Critical Care Medicine of Jena University Hospital in Germany. His main research contribution is immunomodulation in sepsis and in auto-inflammatory disorders for which he was awarded the Young Investigator Research Award by the European Society of Clinical Microbiology and Infectious Diseases. He has 446 publications in international peer-reviewed journals with 21,700 citations and an h-index of 73. He has contributed to the development of clarithromycin for the immunomodulatory treatment of septic shock, the recognition of hidradenitis suppurativa (HS) as an auto-inflammatory disorder, and in the licensing of adalimumab for the treatment of (HS). He is chairing the Hellenic Sepsis Study Group. He was the leading investigator who ran the phase 2 and phase 3 programs ending in the approval of anakinra for COVID-19 pneumonia in adults by the European Medicines Agency.